# Clinical Trial Landscape: 14_renal_cell_io_resistant

*Generated: 2026-01-05 18:34:11*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 4

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 24 | ████ 24.0% |
| Phase 1 | 20 | ████ 20.0% |
| Phase 1/Phase 2 | 19 | ███ 19.0% |
| Unknown | 14 | ██ 14.0% |
| Phase 3 | 11 | ██ 11.0% |
| Not Applicable | 9 | █ 9.0% |
| Early Phase 1 | 1 |  1.0% |
| Phase 2/Phase 3 | 1 |  1.0% |
| Phase 4 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 94 (94.0%)
- **Not yet recruiting**: 4 (4.0%)
- **Enrolling by invitation**: 2 (2.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 10 |
| M.D. Anderson Cancer Center | 8 |
| Dana-Farber Cancer Institute | 5 |
| Mayo Clinic | 4 |
| Jonsson Comprehensive Cancer Center | 3 |
| University of Texas Southwestern Medical Center | 2 |
| University of Colorado, Denver | 2 |
| Massachusetts General Hospital | 2 |
| National Institutes of Health Clinical Center (CC) | 1 |
| University of Nebraska | 1 |
| University of Utah | 1 |
| Megan Daly, MD | 1 |
| Xynomic Pharmaceuticals, Inc. | 1 |
| Rahul Aggarwal | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 13 |
| Biospecimen Collection | 11 |
| Computed Tomography | 10 |
| Nivolumab | 9 |
| Magnetic Resonance Imaging | 8 |
| Questionnaire Administration | 7 |
| Bevacizumab | 4 |
| Biopsy | 4 |
| Cabozantinib | 4 |
| Ipilimumab | 4 |
| Placebo | 3 |
| Bone Scan | 3 |
| Positron Emission Tomography | 3 |
| Carboplatin | 3 |
| Ceralasertib | 2 |
| Olaparib | 2 |
| Durvalumab | 2 |
| Gemcitabine | 2 |
| Biopsy Procedure | 2 |
| Electronic Health Record Review | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 10 |
| South Korea | 9 |
| France | 8 |
| Canada | 7 |
| Australia | 7 |
| Italy | 6 |
| Netherlands | 6 |
| Germany | 6 |
| Israel | 6 |
| United Kingdom | 5 |
| Japan | 5 |
| China | 3 |
| Poland | 2 |
| Belgium | 2 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| renal cell carcinoma | manual | 1.0 |
| clear cell renal cell carcinoma | llm | 0.9 |
| RCC | llm | 0.8 |
| clear cell carcinoma | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06863311](https://clinicaltrials.gov/study/NCT06863311) | Phase 2 | Recruiting | Karie Runcie | EXACT: Randomized Phase II Trial of... |
| [NCT07092566](https://clinicaltrials.gov/study/NCT07092566) | Phase 3 | Recruiting | Wake Forest Universi... | Efficacy of Ropivacaine Epinephrine... |
| [NCT06770855](https://clinicaltrials.gov/study/NCT06770855) | Not Applicable | Not yet recruiting | Abramson Cancer Cent... | A Phase II Study of Total Consolida... |
| [NCT06794229](https://clinicaltrials.gov/study/NCT06794229) | Phase 2 | Recruiting | Qian Qin | A Phase II, Open-label, Single-arm ... |
| [NCT07043608](https://clinicaltrials.gov/study/NCT07043608) | Phase 2 | Not yet recruiting | Kelly Fitzgerald, MD | A Phase II Study of Zanzalintinib f... |
| [NCT07072234](https://clinicaltrials.gov/study/NCT07072234) | Phase 1 | Recruiting | M.D. Anderson Cancer... | Phase I Study of Allogeneic Transfo... |
| [NCT07124000](https://clinicaltrials.gov/study/NCT07124000) | N/A | Recruiting | AstraZeneca | Effectiveness of T-DXd Across HER2-... |
| [NCT06966024](https://clinicaltrials.gov/study/NCT06966024) | Phase 1 | Recruiting | Deciphera Pharmaceut... | An Open-label, Phase 1 Study of DCC... |
| [NCT06910657](https://clinicaltrials.gov/study/NCT06910657) | Phase 1 | Recruiting | ViroMissile, Inc. | A First-in-human, Phase I, Multi-ce... |
| [NCT07010978](https://clinicaltrials.gov/study/NCT07010978) | Not Applicable | Recruiting | Massachusetts Genera... | R34 Study 2 - Pilot RCT Testing the... |
| [NCT06866262](https://clinicaltrials.gov/study/NCT06866262) | Phase 1/Phase 2 | Recruiting | University of Michig... | Phase I/II Trial of Inulin Gel in C... |
| [NCT06732401](https://clinicaltrials.gov/study/NCT06732401) | Phase 3 | Recruiting | National Cancer Inst... | A Randomized Phase III Trial of Che... |
| [NCT07077083](https://clinicaltrials.gov/study/NCT07077083) | Phase 2 | Not yet recruiting | Massachusetts Genera... | A Pilot Study of 89Zr-girentuximab ... |
| [NCT06940518](https://clinicaltrials.gov/study/NCT06940518) | Phase 2 | Recruiting | M.D. Anderson Cancer... | Phase II Trial of Ivonescimab in Pr... |
| [NCT06919666](https://clinicaltrials.gov/study/NCT06919666) | Phase 1/Phase 2 | Recruiting | University of Colora... | Phase Ib/II Study of NT219 in Combi... |
| [NCT06948552](https://clinicaltrials.gov/study/NCT06948552) | Phase 2 | Not yet recruiting | Henry Ford Health Sy... | A Phase II Study on Photodynamic Di... |
| [NCT06805825](https://clinicaltrials.gov/study/NCT06805825) | Phase 1 | Recruiting | Novelty Nobility, In... | A Phase 1 Dose Escalation and Expan... |
| [NCT06764095](https://clinicaltrials.gov/study/NCT06764095) | Phase 4 | Recruiting | Mayo Clinic | CAST-AI: Cystectomy After Systemic ... |
| [NCT06677190](https://clinicaltrials.gov/study/NCT06677190) | Phase 2 | Recruiting | Dana-Farber Cancer I... | A Phase II Trial of Belzutifan in P... |
| [NCT06500455](https://clinicaltrials.gov/study/NCT06500455) | Phase 3 | Recruiting | NRG Oncology | Phase III Trial of Single Fraction ... |
| [NCT06704724](https://clinicaltrials.gov/study/NCT06704724) | Phase 1 | Recruiting | Pfizer | A PHASE 1 OPEN-LABEL STUDY OF PF-07... |
| [NCT06639074](https://clinicaltrials.gov/study/NCT06639074) | Phase 2 | Recruiting | Mayo Clinic | MC1963 Folate Receptor Alpha Dendri... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06222593](https://clinicaltrials.gov/study/NCT06222593) | Phase 1/Phase 2 | Recruiting | State University of ... | A Phase I/II Study to Evaluate the ... |
| [NCT06447103](https://clinicaltrials.gov/study/NCT06447103) | Phase 2 | Recruiting | Jonsson Comprehensiv... | 89Zr-DFO-GmAb PET/CT vs Contrast-En... |
| [NCT05896839](https://clinicaltrials.gov/study/NCT05896839) | Phase 1/Phase 2 | Recruiting | National Cancer Inst... | A Phase 2 Study of Nivolumab and Ip... |
| [NCT06332755](https://clinicaltrials.gov/study/NCT06332755) | Phase 1 | Recruiting | LG Chem | A Phase 1a/1b, First-in-Human, Open... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06234605](https://clinicaltrials.gov/study/NCT06234605) | Phase 1 | Recruiting | HiberCell, Inc. | A Phase 1b, Open-Label, Safety, Tol... |
| [NCT05665361](https://clinicaltrials.gov/study/NCT05665361) | Phase 1/Phase 2 | Recruiting | National Cancer Inst... | A Phase I/II Study of Palbociclib a... |
| [NCT06305767](https://clinicaltrials.gov/study/NCT06305767) | Phase 1/Phase 2 | Recruiting | Merck Sharp & Dohme ... | A Phase 1/2 Study of V940 Plus Pemb... |
| [NCT06242470](https://clinicaltrials.gov/study/NCT06242470) | Phase 1 | Recruiting | MacroGenics | A Phase 1/1b First-in-Human, Open L... |
| [NCT06005818](https://clinicaltrials.gov/study/NCT06005818) | Phase 2 | Recruiting | University of Alabam... | Molecular Residual Disease (MRD) Gu... |
| [NCT05931393](https://clinicaltrials.gov/study/NCT05931393) | Phase 2 | Recruiting | University of Texas ... | Phase 2, Open-label, Single Cohort,... |
| [NCT06040762](https://clinicaltrials.gov/study/NCT06040762) | Not Applicable | Recruiting | University of Washin... | The "Get Moving Trial": A Phase I/I... |
| [NCT05969496](https://clinicaltrials.gov/study/NCT05969496) | Phase 2 | Recruiting | University of Colora... | Neoadjuvant Pembrolizumab and Axiti... |
| [NCT05874921](https://clinicaltrials.gov/study/NCT05874921) | N/A | Recruiting | UroGen Pharma Ltd. | uTRACT Jelmyto Registry: A Multicen... |
| [NCT06026410](https://clinicaltrials.gov/study/NCT06026410) | Phase 1 | Recruiting | Kura Oncology, Inc. | Phase 1, First-in-Human, Multicente... |
| [NCT06101290](https://clinicaltrials.gov/study/NCT06101290) | Not Applicable | Recruiting | University of Califo... | Locally Ablative TherapY in Oligo-P... |
| [NCT05899361](https://clinicaltrials.gov/study/NCT05899361) | Not Applicable | Recruiting | Dana-Farber Cancer I... | A Pilot Study of a Novel Imaging Pr... |
| [NCT06270706](https://clinicaltrials.gov/study/NCT06270706) | Phase 1 | Recruiting | Pliant Therapeutics,... | A Phase 1a/1b Multicenter, Open-lab... |
| [NCT05663710](https://clinicaltrials.gov/study/NCT05663710) | Phase 1/Phase 2 | Recruiting | M.D. Anderson Cancer... | Phase 1b/2 Study of Combination 177... |
| [NCT04919629](https://clinicaltrials.gov/study/NCT04919629) | Phase 2 | Recruiting | Roswell Park Cancer ... | Randomized Phase 2 Trial of APL-2 W... |
| [NCT05700461](https://clinicaltrials.gov/study/NCT05700461) | Phase 1 | Recruiting | Wenxin Xu | Pilot Study of an Implantable Micro... |
| [NCT05703854](https://clinicaltrials.gov/study/NCT05703854) | Phase 1/Phase 2 | Recruiting | M.D. Anderson Cancer... | Phase I/II Study of CAR.70-engineer... |
| [NCT05614739](https://clinicaltrials.gov/study/NCT05614739) | Phase 1 | Recruiting | Eli Lilly and Compan... | FORAGER-1: A Phase 1, Open-Label, M... |
| [NCT05319015](https://clinicaltrials.gov/study/NCT05319015) | Phase 2 | Recruiting | University of Texas ... | A Phase II Study of the Safety and ... |
| [NCT05600777](https://clinicaltrials.gov/study/NCT05600777) | Phase 3 | Recruiting | Bellus Health Inc. -... | A Phase 3, 24-Week, Randomized, Dou... |
| [NCT05361720](https://clinicaltrials.gov/study/NCT05361720) | Phase 2 | Recruiting | Vanderbilt-Ingram Ca... | Optimal Treatment by Invoking Biolo... |
| [NCT05584670](https://clinicaltrials.gov/study/NCT05584670) | Phase 1/Phase 2 | Recruiting | Sanofi | A Phase 1/2, Open Label, First-in-h... |

*... and 50 more trials (see trials.csv for full list)*
